180 Life Sciences to Acquire Aptose Biosciences
Ticker: APTOF · Form: 8-K · Filed: Jun 20, 2024 · CIK: 882361
Sentiment: neutral
Topics: acquisition, merger, biotech
TL;DR
APTOS getting bought by 180 Life Sciences, deal expected Q3 2024.
AI Summary
Aptose Biosciences Inc. announced on June 18, 2024, that it has entered into a definitive agreement to be acquired by 180 Life Sciences Corp. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This acquisition will combine two companies focused on developing novel therapeutics.
Why It Matters
This acquisition could lead to the consolidation of resources and expertise in the development of new treatments, potentially accelerating the path to market for their respective drug candidates.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the integration of the two companies may present challenges.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- 180 Life Sciences Corp. (company) — Acquiring company
- June 18, 2024 (date) — Date of agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces the definitive agreement for the acquisition of Aptose Biosciences Inc. by 180 Life Sciences Corp.
Who is acquiring Aptose Biosciences Inc.?
Aptose Biosciences Inc. is being acquired by 180 Life Sciences Corp.
When is the acquisition expected to close?
The acquisition is expected to close in the third quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the former name of Aptose Biosciences Inc.?
Aptose Biosciences Inc. was formerly known as LORUS THERAPEUTICS INC. and IMUTEC PHARMA INC.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-06-18 18:03:06
Filing Documents
- f8k_061824.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-003515.txt ( ) — 224KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_061824_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On June 18, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated June 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: June 18, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer